NCT02065856

An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: ALK-Abelló A/S · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This trial is an open, national, multi-centre trial. The trial will be initiated in December 2013 and subjects will receive treatment for 6 weeks. Safety monitoring will be performed in an ongoing basis through a Clinical Safety Group with immediate access to Adverse Events registered in the clinical database. The composition, procedures and deliverables of the Clinical Safety Group will be detailed in a Safety Agreement prior to trial start.

Conditions

• Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen

Interventions

Type	Name	Description
BIOLOGICAL	AVANZ Salsola	AVANZ Salsola

Timeline

• Start date: 2013-12-01
• Primary completion: 2014-08-01
• Completion: 2014-12-01
• First posted: 2014-02-19
• Last updated: 2015-01-14

Locations

1 site across 1 country: Spain